Skip to main content

Actuate Therapeutics Inc(ACTU-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.29
Day High2.39
Open:2.31
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Actuate Therapeutics Inc

Select a category then submit the form to load news
ACCESS Newswire
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
GlobeNewswire
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
GlobeNewswire
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
GlobeNewswire
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
Tipranks
Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Teva Pharmaceutical (TEVA)
Tipranks
Actuate Therapeutics reports positive Phase 2 pancreatic cancer data
GlobeNewswire
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at...
GlobeNewswire
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
GlobeNewswire
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
GlobeNewswire
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
Tipranks
Actuate Therapeutics Signs $100M Sales Agreement
Tipranks
Craig-Hallum Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)
Tipranks
Actuate Therapeutics Announces Public Offering of Shares
GlobeNewswire
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
ACCESS Newswire
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy
Tipranks
Craig-Hallum Remains a Buy on Actuate Therapeutics, Inc. (ACTU)
Tipranks
Craig-Hallum Keeps Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)
GlobeNewswire
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
Tipranks
Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum
GlobeNewswire
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
GlobeNewswire
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
GlobeNewswire
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Tipranks
Craig-Hallum Initiates a Buy Rating on Actuate Therapeutics, Inc. (ACTU)
Barchart
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double
pile of blue medical masks by Say-Cheese via iStock
GlobeNewswire
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
Tipranks
Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU)
GlobeNewswire
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
GlobeNewswire
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

Profile

Actuate Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers. The company's lead product includes elraglusib. Actuate Therapeutics Inc. is based in FORT WORTH, Texas.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.